The third International Gamma Knife Research Foundation Meeting is designed to increase scientific knowledge-base and levels of evidence related to the use of Gamma Knife. An international faculty of pioneers and leaders will present and discuss clinical advances and innovative therapies.
This symposium is designed for neurosurgeons, radiation oncologists, medical oncologists, radiologists, neurotologists, medical physicists, researchers, business managers, resident/fellow physicians, nurses and physician assistants.
At the completion of this course, participants should be able to:
- Explain current concepts of immunotherapy for primary and metastatic tumors in the brain.
- Discuss the role of radiosurgery as an immune modulator for treatment of intracranial neoplasm.
- Identify research opportunities in immunotherapy that can be conducted with Gamma Knife radiosurgery.
- Describe the current state of intracranial lesioning in the brain as a therapeutic option for patients with functional disorders and tumors -- including focused ultrasound, laser thermocoagulation and Gamma Knife radiosurgery.
- Identify opportunities of synergy with invasive and noninvasive lesioning techniques.
- Define the biologic rationale of radiosurgery and clinical evidence in treatment of benign tumors: meningiomas and pituitary adenomas.
- Describe and review current radiosurgery options for vascular pathology including aneurysms, AVMs, and to propose potential future clinical trials.
- Describe imaging outcomes after Gamma Knife radiosurgery.
- Discuss the current role of informatics in medicine and identify the potential applications for outcome metrics as they relate to Gamma Knife radiosurgery.
- Identify the current clinical evidence as it relates to Gamma Knife ICON and its functionality.
- Distinguish the role of proton and photons in stereotactic radiosurgery as they relate to the introduction of the Gamma Knife ICON for radiosurgical treatment.
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum
of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 7.75 Category 1 credits for completing this activity
The Perelman School of Medicine at the University of Pennsylvania, Office of Continuing Medical Education, adheres to the ACCME Standards for Commercial Support. Faculty disclosure information will be made available in the
conference materials and syllabi. Faculty members are also expected to disclose to participants any discussion of off-label and / or investigational use of pharmaceutical products or devices within their presentations.
The abstract submission site is open to all trainees, neurosurgeons, radiation oncologists, radiologists, neurotologists, medical physicists, researchers, resident/fellow physicians, nurses and physician assistants.
Abstract submission ends at 5pm ET, Friday, April 21, 2017.
Accepted abstracts will be presented in an ePoster format (electronic PowerPoint). No printed poster boards will be on display. Select abstract authors will be invited to give an 8–10 minute presentation during an educational session on a related topic.
- Malignant Tumors
- Benign Tumor Radiosurgery
- Follow-Up GK
Submission of an abstract constitutes a commitment by the first author to attend the annual meeting and address attendee questions if the abstract is accepted
- Abstracts must be submitted online through the registration portal.
- You may register now and return later to submit your abstract via the registration portal by choosing "update registration” (top of the registration page) and by checking "Overwrite Previous Response” (bottom of registration page).
- Abstract submissions are limited to 2,500 characters.
- Abstracts must be balanced and contain no commercial promotional content. Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract.
- Abstracts must be proofread carefully to avoid errors before they are submitted. The University of Pennsylvania is not authorized to make changes to a submission. This includes typographical errors to the abstract title or text as well as additions or deletions of author names. Your abstract, if selected, will be published exactly as submitted.
Notification of acceptance will be sent to the first author via email on Friday, May 19th.
Awards will be presented for the best overall abstract and for young investigators (under 30 years).
Registration and Travel
The first authors of accepted abstracts must register for and attend the meeting. Abstract authors are responsible for their registration and travel arrangements. The University of Pennsylvania does not provide honorarium or reimbursement of travel expenses.